LOCALLY ADVANCED SOLID TUMOR
Clinical trials for LOCALLY ADVANCED SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED SOLID TUMOR trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer combo study halted early
Disease control TerminatedThis study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated May 17, 2026 09:18 UTC
-
Targeted drug shows promise for rare genetic cancers, but study halted early
Disease control TerminatedThis study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific PALB2 gene mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stopped early, so results are …
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Experimental cancer pill targets genetic weakness in tumors
Disease control TerminatedThis study tested an experimental oral drug called TNG908 in adults with advanced solid tumors that lack the MTAP gene. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, so results are limited.
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested an experimental drug called TransCon TLR7/8 Agonist, given as an injection into tumors, either alone or with another drug (pembrolizumab). It aimed to find a safe dose and check for side effects in people with advanced solid tumors that had stopped responding to…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated May 12, 2026 13:43 UTC